The hbsag reductions are more substantial now that the integrated hbsag gene is also included in the interfering action of the drug. But it is still far from the level needed to allow an antibody response to surface.
The reduction results from temporary interfering with messenger RNA processing and is not the result of the elimination of infected or integrated cells. Unless a strong and effective tell response is triggered by these reductions, that will kill those cells, the value will eventually go up again.
The hbsag reduction achieved by the nap treatments was much stronger and still did not achieve permanent control unless immune activation by interferon or thymusin alpha was added.
That is great news indeed, but just to be clear... is circulating hbsag = hbsag quantity?
This is good and encouraging news with so much reduction in hbsag after just three doses. But what I see missing is there is no mention of wether the test groups developed any anti-hbs. Probably the hope is that their own immune system is going to respond to the infection, after a considerable and sustained reduction in hbsag?
Also I've seen in the news that the stocks of Arrowhead have increased by almost 50% in value after the release of this news. Good for those who have invested in those stocks, but for us hbvers, our concern is first and foremost a drug that could help us cure from this menace.
just read goods news on this. maybe study4hope can give his experience on it.